Epimedin K



Compound IDCDAMM02031
Common nameEpimedin K
IUPAC name[5-acetyloxy-6-[5-acetyloxy-3-hydroxy-2-[5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-4-oxo-7-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-3-yl]oxy-6-methyloxan-4-yl]oxy-3,4-dihydroxyoxan-2-yl]methyl acetate
Molecular formulaC45H56O23

Experimental data

Retention time17.85
Adduct[M+H]+
Actual mz965.329
Theoretical mz965.328
Error0.34
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.0835

Identifiers and class information

Inchi keyAHIXHBMUHIBLGS-KQYAEQGENA-N
SmilesO=C(OCC1OC(OC2C(O)C(OC=3C(=O)C4=C(O)C=C(OC5OC(CO)C(O)C(O)C5O)C(=C4OC3C=6C=CC(OC)=CC6)CC=C(C)C)OC(C)C2OC(=O)C)C(OC(=O)C)C(O)C1O)C
SuperclassPhenylpropanoids and polyketides
ClassFlavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)13
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)22
Number of reactive functional groups (#rtvFG)6
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)964.924
Computed dipole moment(dipole)2.003
Total solvent accessible surface area (SASA)1187.79
Hydrophobic component of SASA (FOSA)711.992
Hydrophilic component of SASA (FISA)372.865
Pie component of the SASA (PISA)102.93
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2558.93
Number of hydrogen bond donors (donorHB)7
Number of hydrogen bond acceptors (accptHB)29.2
Free energy of solvation of dipole (dip^2/V)0.0015683
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0650419
Globularity descriptor (glob)0.761725
Predicted polarizability in cubic angstroms (QPpolrz)83.111
Predicted hexadecane/gas partition coefficient (QPlogPC16)26.397
Predicted octanol/gas partition coefficient (QPlogPoct)54.955
Predicted water/gas partition coefficient (QPlogPw)39.975
Predicted octanol/water partition coefficient (QPlogPo/w)0.095
Predicted aqueous solubility (QPlogS)-3.545
Conformation-independent predicted aqueous solubility (CIQPlogS)-7.609
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.878
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)2.884
Predicted brain/blood partition coefficient (QPlogBB)-5.047
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.889
Predicted skin permeability, log Kp (QPlogKp)-5.917
PM3 calculated ionization potential (IP(ev))8.793
PM3 calculated electron affinity (EA(eV))0.64
Number of likely metabolic reactions (#metab)12
Prediction of binding to human serum albumin (QPlogKhsa)-1.171
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)351.625
Number of nitrogen and oxygen atoms (#NandO)23
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
P43166CA7Carbonic anhydrase VIIT37541SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
O76074PDE5APhosphodiesterase 5AT07663SwissTargetPrediction
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SEA
P14679TYRTyrosinaseT97035SEA
P20916MAGMyelin-associated glycoprotein (by homology)T95286SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T07663DI0190Hypertension[ICD-11: BA00-BA04]O76074PDE5A
T07663DI0213Innate/adaptive immunodeficiency[ICD-11: 4A00]O76074PDE5A
T07663DI0378Sexual dysfunction[ICD-11: HA00-HA01]O76074PDE5A
T07663DI0411Tonus and reflex abnormality[ICD-11: MB47]O76074PDE5A
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T95286DI0219Ischaemic/haemorrhagic stroke[ICD-11: 8B20]P20916MAG
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025